Tibsovo
New Treatment OK’d for Newly Diagnosed IDH1-Mutant AML
The FDA approved the combination of ivosidenib (Tibsovo, Servier) plus azacitidine for adults aged 75 years and ...
MAY 27, 2022
FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated UC
The FDA approved ivosidenib (Tibsovo, Servier) for adults with previously treated, locally advanced or metastatic ...
AUGUST 30, 2021
Tibsovo Offers Oral Option for IDH1-Positive Relapsed/Refractory AML
The FDA has approved ivosidenib (Tibsovo, Agios) for the treatment of adults with relapsed or refractory acute ...
JULY 22, 2018
Load more